Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT

Characterization of Tumor Responses in Patients With Unresectable Hepatocellular Carcinoma Treated With Lenvatinib in the Phase 3 Randomized Trial, REFLECT

Introduction: In REFLECT, lenvatinib was noninferior to sorafenib in terms of overall survival (OS) in patients with unresectable hepatocellular carcinoma (uHCC; median 13.6 vs 12.3 months; HR 0.92, 95% CI 0.79-1.06). The objective response rate (ORR) with lenvatinib was 18.8% by blinded independent...

Full description

Bibliographic Details
Main Authors:	Richard S. Finn, Shukui Qin, Fabio Piscaglia, Thomas R Jeffry Evans, Jennifer J. Knox, Carlos López López, Zahra Ramji, Min Ren, Kalgi Mody, Arndt Vogel, Masatoshi Kudo
Format:	Article
Language:	English
Published:	Karger Publishers 2024-02-01
Series:	Liver Cancer
Online Access:	https://beta.karger.com/Article/FullText/537947

Similar Items

A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
by: Masatoshi Kudo, et al.
Published: (2023-11-01)

Analysis of Survival and Response to Lenvatinib in Unresectable Hepatocellular Carcinoma
by: Kei Amioka, et al.
Published: (2022-01-01)

Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study
by: Richard S. Finn, et al.
Published: (2024-02-01)

Safety and Effectiveness of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice: An Observational Post-Marketing Study in Japan
by: Junji Furuse, et al.
Published: (2023-01-01)

Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma in Real Clinical Practice
by: V. V. Petkau, et al.
Published: (2022-12-01)

Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib
by: Kei Endo, et al.
Published: (2020-08-01)

Analysis of Lenvatinib’s Efficacy against Intermediate-Stage Unresectable Hepatocellular Carcinoma
by: Kei Amioka, et al.
Published: (2022-10-01)

A Case of Unresectable Combined Hepatocellular-Cholangiocarcinoma Successfully Treated with Lenvatinib
by: Takahiro Osuga, et al.
Published: (2022-03-01)

Selection of Systemic Treatment Regimen for Unresectable Hepatocellular Carcinoma: Does Etiology Matter?
by: Masatoshi Kudo
Published: (2022-06-01)

Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib
by: Yen-Yang Chen, et al.
Published: (2020-11-01)

Sorafenib, Lenvatinib, or Lenvatinib Combining PD-1 Inhibitors Plus TACE in Unresectable Hepatocellular Carcinoma: A Retrospective Analysis
by: Shu Zhao MD, et al.
Published: (2022-10-01)

Prognostic model for predicting outcome and guiding treatment decision for unresectable hepatocellular carcinoma treated with lenvatinib monotherapy or lenvatinib plus immunotherapy
by: De-Zhen Guo, et al.
Published: (2023-02-01)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
by: Shigeki Yano, et al.
Published: (2023-11-01)

Machine Learning to Predict the Response to Lenvatinib Combined with Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma
by: Jun Ma, et al.
Published: (2023-01-01)

Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
by: He-nan Qin, et al.
Published: (2022-11-01)

Objective Response to Systemic Therapy Is a Strong Predictor of Overall Survival in Patients with Unresectable Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2023-11-01)

Exploratory Analysis of Lenvatinib Therapy in Patients with Unresectable Hepatocellular Carcinoma Who Have Failed Prior PD−1/PD-L1 Checkpoint Blockade
by: Tomoko Aoki, et al.
Published: (2020-10-01)

Clinical Significance of Adverse Events for Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Retrospective Study
by: Shigeo Shimose, et al.
Published: (2020-07-01)

Immune Checkpoint Inhibitors plus Anti-VEGF/TKIs Combined with TACE (Triple Therapy) in Unresectable Hepatocellular Carcinoma
by: Masatoshi Kudo
Published: (2024-04-01)

Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
by: Shijie Wang, et al.
Published: (2022-11-01)

TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
by: Zhanwang Xiang MD, et al.
Published: (2023-09-01)

Weekends-Off Lenvatinib for Unresectable Hepatocellular Carcinoma Improves Therapeutic Response and Tolerability Toward Adverse Events
by: Hideki Iwamoto, et al.
Published: (2020-04-01)

Real-World Effectiveness of Sorafenib versus Lenvatinib Combined with PD-1 Inhibitors in Unresectable Hepatocellular Carcinoma
by: Hsueh-Chien Chiang, et al.
Published: (2023-01-01)

Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
by: Liwei Sun, et al.
Published: (2022-09-01)

Real‐world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice
by: Amit G. Singal, et al.
Published: (2023-01-01)

Clinical usefulness of geriatric assessment in elderly patients with unresectable hepatocellular carcinoma receiving sorafenib or lenvatinib therapy
by: Shuhei Sekiguchi, et al.
Published: (2022-11-01)

Prognostic Significance of C-Reactive Protein in Lenvatinib-Treated Unresectable Hepatocellular Carcinoma: A Multi-Institutional Study
by: Taiki Okumura, et al.
Published: (2023-11-01)

Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI
by: Akinori Kubo, et al.
Published: (2021-07-01)

Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma
by: Zijian Yang, et al.
Published: (2022-01-01)

Population Sensitive to Lenvatinib Plus Anti-PD-1 for Unresectable Hepatocellular Carcinoma Infected with Hepatitis B Virus
by: Chang X, et al.
Published: (2023-06-01)

Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
by: Jinfeng Wang MM, et al.
Published: (2023-05-01)

Albumin-Bilirubin Grade Analyses of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Unresectable Hepatocellular Carcinoma: A Post Hoc Analysis of the Phase III IMbrave150 Study
by: Masatoshi Kudo, et al.
Published: (2023-03-01)

Controlling Nutritional Status (CONUT) Score is Associated with Overall Survival in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib: A Multicenter Cohort Study
by: Shigeo Shimose, et al.
Published: (2020-04-01)

Deep learning of pretreatment multiphase CT images for predicting response to lenvatinib and immune checkpoint inhibitors in unresectable hepatocellular carcinoma
by: Nan-Qing Liao, et al.
Published: (2024-12-01)

The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study
by: Kaoru Tsuchiya, et al.
Published: (2021-05-01)

Usefulness of Circulating CYFRA21-1 in Patients as a Biomarker in Patients Taking Sorafenib or Lenvatinib for Unresectable Hepatocellular Carcinoma
by: Hitomi Takada, et al.
Published: (2021-08-01)

A Retrospective Analysis of Conversion Therapy with Lenvatinib, Sintilimab, and Arterially-Directed Therapy in Patients with Initially Unresectable Hepatocellular Carcinoma
by: Gan L, et al.
Published: (2023-04-01)

Similar efficacy and safety between lenvatinib versus atezolizumab plus bevacizumab as the first‐line treatment for unresectable hepatocellular carcinoma
by: Chung‐Wei Su, et al.
Published: (2023-03-01)

Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study
by: Jian Huang, et al.
Published: (2023-07-01)

Transarterial Chemoembolization Combined with Atezolizumab Plus Bevacizumab or Lenvatinib for Unresectable Hepatocellular Carcinoma: A Propensity Score Matched Study
by: Zhao C, et al.
Published: (2023-07-01)